Connection

WENDY KEITEL to Adjuvants, Immunologic

This is a "connection" page, showing publications WENDY KEITEL has written about Adjuvants, Immunologic.
Connection Strength

2.326
  1. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010 Jan 08; 28(3):840-8.
    View in: PubMed
    Score: 0.289
  2. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
    View in: PubMed
    Score: 0.278
  3. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 2009; 333:323-44.
    View in: PubMed
    Score: 0.274
  4. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
    View in: PubMed
    Score: 0.270
  5. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.167
  6. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.143
  7. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine. 2016 07 19; 34(33):3796-802.
    View in: PubMed
    Score: 0.115
  8. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
    View in: PubMed
    Score: 0.110
  9. Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
    View in: PubMed
    Score: 0.110
  10. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.108
  11. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine. 1993; 11(9):909-13.
    View in: PubMed
    Score: 0.090
  12. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9.
    View in: PubMed
    Score: 0.076
  13. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
    View in: PubMed
    Score: 0.071
  14. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
    View in: PubMed
    Score: 0.071
  15. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.050
  16. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236.
    View in: PubMed
    Score: 0.046
  17. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.021
  18. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
    View in: PubMed
    Score: 0.015
  19. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine. 2006 Aug 14; 24(33-34):5950-9.
    View in: PubMed
    Score: 0.014
  20. Improvement of inactivated influenza virus vaccines. J Infect Dis. 1997 Aug; 176 Suppl 1:S38-44.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.